Funding Agency: Janssen.Ģ019/2020 Apoio Doutoral INPhINIT Incoming. Previous Research ProjectsĢ019/2020 Apoio Educacional. Funding Agency: European Commission HORIZON 2020. Funding Agency: Fellowship Building the future knowledge in mature B cell malignancies attributed by SPH, APCL and Gilead Sciences.Ģ015/2021 Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes. Funding Agency: Merck and Co, NJ, USA.Ģ020/2021 Development of a novel chimeric antigen receptor T cell therapy using B-cell activating factor, for triple targeting of B-cell specific receptors for multiple myeloma and other mature B cell neoplasms. Funding Agency: Fundação para a Ciência e a Tecnologia.Ģ020/2023 Development of Chimeric Antigen Receptor T cell therapy targeting oncological-associated chondroitin sulfate as cancer treatment.Ģ020/2022 CMV infection and CMV-specific T-cell reconstitution in unrelated donor allo-HSCT after in vivo T-cell depletion with ATG: a comparative study of prophlylaxis with letermovir versus standard of care preemptive. More recently, we engaged in developing several novel strategies for CAR T cell therapies of hematologic malignancies and solid tumors.Ģ021/2024 Generation and in-depth characterization of antigen-specific regulatory T cells to be applied in allogeneic hematopoietic stem transplantation. We continue to develop several lines of research in the field of genetic susceptibility for viral and fungal infections after hematopoietic stem cell transplantation.

We are particularly interested in developing strategies that may be translated into the clinical setting, such as the use of pathogen-specific T cells, donor regulatory T cells for GVHD and disease-specific T cells, with the aim of improving patient survival.

Our laboratory aims to identify immunological risk factors and the mechanisms by which these complications emerge post-transplant. Donor immunity emerging post-transplant plays a pivotal role in the protection against pathogens, such as Aspergillus, CMV and EBV, as well as in the development of graft-versus-host disease (GVHD) and graft-versus-leukemia effect. The main research focus of our laboratory is the study of immune reconstitution after hematopoietic stem cell transplantation (HSCT) in humans and the development of strategies that modulate immune responses and tolerance post-transplant. Hematology and Transplantation Immunology

Pt 1007 f